ACR
Delivery · High$10M2mo
Acrux
Biotech · Dermatology
Topical drug delivery technology, LENZETTO hormone therapy
Cash data from Mar 2026 4CFigures from ASX filings · not financial advice
[ VITALS ]
Cash on Hand
$0.6M
Mar 2026 4C
Runway
2moCRITICAL
Based on Mar 2026 4C
Market Cap
$10M
Burn Rate
$0.8M/qtr
Mar 2026 4C
Shares Outstanding
579M
Pipeline Assets
4
Latest Insightprice-sensitive announcements & broker notes
Price-sensitivePartnership29 May 2026
Update - Licensing Lenzetto for Australia for AUD5.4m
Gedeon Richter Plc·out license·Australia
·Milestones$5.4M
3M Price
ACR.ASX$0.016+23.1% 3M
Low $0.009High $0.016
Capital Raises & Buybacks
12mo dilution 29.1%12mo $2M1 raise
Current shares outstanding: 579M
Placement
2026-05-11placement
$1.6M
Other ticker dataInsider activity, holders, grants, publications
expand ›
Insider activity, holders, grants, publications
Director Transactions
3 transactionsLast 90dNo Activity
Buys0
Sells0
PERFORMANCE RIGHTSRoss Dobinsonopen_in_new
2026-06-02
6d after · Acrux licenses Lenzetto for Australian market for AUD5.4m
Catalysts (8)· 2 upcoming · 6 past
Dapsone 7.5% Gel US launch revenue
UpcomingConfirmedremoveMed30 June 2026
Acyclovir Cream 5% FDA decision
UpcomingExpectedremoveMed31 Dec 2026
expand_more6 past catalysts
Expected
Track RecordDelivery Consistency Index
expand ›
Delivery Consistency Index
Historical delivery and spending consistency. Data is limited for recently added companies.
Delivery Consistency Index
Delivery
High100/100
Timeline adherence · phase-adjusted tolerance · recency-weighted · min 3 catalysts
Capital discipline
Med47/100(limited data)
Burn rate stability · stage-adjusted thresholds · runway trend · R&D focus
Hit 6 of 6 guided dates· rolling 2yr· of 8 tracked
Filed 2 of 2 4Cs on time· statutory deadline
What drove these scores · rolling 2yr
arrow_drop_down
Volatile burn rate — 75% quarterly variation — inconsistent spend
arrow_drop_down
1 burn spike — Quarter-on-quarter spend increase >50%
arrow_drop_down
High admin overhead — Only 34% of opex directed to R&D
arrow_drop_up
Lenzetto milestone payments over two years from launch — Delivered 729d early
·
Female Testosterone (Metered Dose Transdermal System) FDA — Acrux strategy focuses on Female Testosterone for low libido — Delivered on time
·
Acrux raises $1.6 million via Share Placement — Delivered on time
·
Proposed issue of securities - ACR — Delivered on time
·
N/A N/A — Capital Gains Tax exemptions remain in place for Acrux — Delivered on time
·
Acrux licenses Lenzetto for Australian market for AUD5.4m — Delivered on time
·
Phase 3+ thresholds — Burn rate variability thresholds adjusted for late-stage development
Completed catalysts
✓Female Testosterone (Metered Dose Transdermal System) FDA — Acrux strategy focuses on Female Testosterone for low libido— Acrux received FDA feedback on completed Phase I and II clinical trials for its Female Testosterone transdermal product, with the FDA providing a viable pathway to proceed to Phase III development. The company is now pursuing a co-development strategy to bring the product to market for HSDD, an area of high unmet need with no currently approved female testosterone treatment in the US.
On time
✓Acrux raises $1.6 million via Share Placement
On time
✓Proposed issue of securities - ACR
On time
✓N/A N/A — Capital Gains Tax exemptions remain in place for Acrux— This announcement relates to Capital Gains Tax exemptions for Acrux as a Pooled Development Fund, not a regulatory milestone. There is no drug approval, designation, or regulatory body involved.
On time
✓Acrux licenses Lenzetto for Australian market for AUD5.4m— Acrux has amended its licensing agreement with Gedeon Richter for Lenzetto® (transdermal Estradiol spray) to include Australian market rights, with potential milestone payments totaling up to AUD 5.4 million over two years from product launch. The product addresses a critical shortage of Menopause Hormone Therapy products in Australia and leverages Acrux's Patchless Patch™ technology, which is already generating EUR 50 million in global sales.
On time
✓Lenzetto milestone payments over two years from launch— Acrux licensed Lenzetto to Gedeon Richter Plc for the Australian market with total milestone payments of up to AUD 5.4 million, including upfront signing, TGA regulatory approval, and commercial sales milestones. The licensing deal has been executed, triggering the initial milestone structure.
729d early
Outcome quality (positive/negative readouts) reflects the science, not execution — shown above but excluded from the score.
These metrics reflect historical operational data only. They are not predictive of future performance, do not constitute investment advice, and should not be used as the basis for any investment decision.